Patient Profiles
1
Assess Patient Data
Visualize patient data over their participation timeline.
2
atypical Patients
Be guided to atypical patient data by the system.
3
Review Progress
Record, review, and track progress.
4
Collaborate
Share Patient Profiles with other stakeholders.
Hover over the toggles to discover the features.
FIND ATYPICAL PATIENTS
Coupling Patient Profiles with Central Statistical Monitoring offers a more targeted approach for clinical teams to prioritize the investigation of atypical patients, by identifying anomalies in data and ranking patients by their relative degree of atypicality.
1
Assess Patient Data
Visualize patient data over their participation timeline.
2
atypical Patients
Be guided to atypical patient data by the system.
3
Review Progress
Record, review, and track progress.
4
Collaborate
Share Patient Profiles with other stakeholders.
Hover over the toggles to discover the features.
- Gain detailed insight into patient experiences.
- Target patients that matter the most.
- Benefit from a customizable set of visualization options, including the ability to visually asses a chronological view of a patient’s visit, investigational product exposure, adverse events and concomitant medications, along with any additional patient information that’s relevant.
- Quickly and effectively characterize risk signals and enable centralized medical and safety reviews.
- Perform Medical Review directly in the CluePoints platform
- Use visual Patient Profiles to explore patient data and validate operational issues
Got a Question?
Whether you’re looking to get started or need support, we’re here to help!
Featured Resources
Tufts CSDD Impact Report
This study takes a proactive approach to understanding the dynamics between the enthusiasm around and adoption of RBQM, designed to enhance clinical trial quality and efficiency.
Featured Webinar
RBQM Adoption & ICH E6(R3) Updates
This recorded webinar dissects the Tufts CSDD Impact Report as well as new clinical trial execution models and ICH E6(R3) regulatory guidance updates.
We're Kind of a Big Deal.
7,000
Platform Users
1,200
Studies De-Risked
100,000
Issues Detected